Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion type Assertion NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_head.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion evidence source_evidence_literature NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion SIO_000772 23635776 NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion wasDerivedFrom befree-20140225 NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion wasGeneratedBy ECO_0000203 NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.